Ann: US FDA Completes Review of IHL-42x IND Application, page-67

Hi @Tv
Phase 3 will be conducted over a large number of patients to show efficiency over the standard drug used now. Joel touched on this and hence the 400-600 patients. If this phase is successful and being patent it's going to be hard for other companies to show their phase 3 drug better the ours before any approvals to bring that drug into production. This is why it's so pivotal to IHL. Also to answer your question IMO phase 3 will take up a larger portion in the 12 months phase 2/3 timeline
Also there will be no CR due to the Redomicile. This is not their intention. Yes there will be CR's in the future as trial cost money but Joel and Troy"s focus is getting the MC to a more true value to reflect the company's 28 platforms and the advancements made thus far.
We spoke at lengths in relation to IHL 42X. Both we're extremely excited about the prospect of IHL-42X as results so far show far better efficiency than what is available on the market now. We just need to excersise patience, get the Redomicile D&D and move on. There is a reason BC hopped on board and why the FDA approved these trials with no further explanation or requirements needed. A credit to Bob and management. The market will be watching and with interim analysis at 3-6 and 12 months we will be kept up to date. The aim is to increase IHL42X's value upon each announcement, getting our MC to a more respectable level and then CR when needed. Watch this space. Sounds like Reamed are.
GL @Tv